Most studies on the potential of marijuana, classic hallucinogens, 3,4-methylenedioxymethamphetamine, and ketamine have been small with methodological flaws, but the promising results from existing studies suggest that larger studies are warranted, said William M. Suavé, MD, medical director, Greenbrook TMS NeuroHealth Centers, during a presentation on the therapeutic potential of illicit drugs.
During a session at the 2017 Neuroscience Education Institute (NEI) Congress, William M. Suavé, MD, medical director, Greenbrook TMS NeuroHealth Centers, gave a presentation on the therapeutic potential of several illicit drugs.
The first drug Suavé focused on was marijuana. Substantial evidence from the National Academies of Sciences show that cannabis is beneficial for chronic pain, chemotherapy-induced nausea, and spasticity in multiple sclerosis (according to patient reports). However, the evidence also shows that cannabis is associated with the risk of respiratory symptoms, motor vehicle crashes, lower birth weight, and psychosis.
“There is evidence that some individuals are replacing the use of conventional pain medication with cannabis,” said Suavé. Cannabis was associated with a 65% reduction of opioid use in patients with chronic pain.
However, there are adverse effects associated with both short-term and long-term use of cannabis, said Suavé. Effects of short-term use include impaired short-term memory, motor coordination, and judgment; and paranoid ideation and psychotic symptoms in response to high doses of tetrahydrocannabinol. Effects of long-term or heavy use include altered brain development, symptoms of chronic bronchitis, increased risk of psychosis disorders, and cognitive impairment.
According to Suavé, medical marijuana is not a viable prescription option currently because drug approval standards require a consistent, pure, and well-defined chemical formulation; safety data in healthy populations and in specific medical disorders; a consistent, well-defined pharmacokinetic profile; efficacy data in specific medical disorders; and warnings regarding all potential side effects. Currently, for medical marijuana, compounds may vary from plant to plant, dosing is not well regulated, and there are residual impurities.
Suavé then discussed the use of psychedelics due to the renewed interest in the therapeutic value of hallucinogens. Typically 1 or 2 doses would be delivered in the context of psychotherapy to aid several disorders including depression, anxiety, addiction, and alcoholism. Classic hallucinogens include 2 classes of alkaloids: tryptamines and phenethylamines. Non-classic hallucinogens include 3,4-methylenedioxymethamphetamine (MDMA) and dissociative anesthetics.
The mechanism of action for classic hallucinogens is the exertion of effects primarily through the prefrontal cortical 5HT2A receptor agonism. Most studies report therapeutic effects that correlate with the level of “mystical” experience, said Suavé. There is a decreased brain connectivity in the default mode network, followed by the establishment of new connections.
“Hypothetically, this rewiring of the brain replaces disputed connections underlying psychiatric conditions with healthier connections,” said Suavé.
Small studies have shown the benefits of psilocybin on treatment-resistant depression; anxiety and depression associated with cancer; obsessive complusive disoder; and smoking cessation. A meta-analysis of randomized control trials concluded that a single dose of lysergic acid diethylamide, aka LSD, in the context of an alcoholism treatment program may decrease alcohol use.
Risks of these classic hallucinogens include dizziness, weakness, dilated pupils, tremors, and rare prolonged psychosis.
MDMA, also known as “ecstasy,” originated as a potential therapeutic agent. The FDA has recently approved phase 3 trials testing MDMA for patients with posttraumatic stress disorder (PTSD). MDMA has shown to increase motivation to engage in therapy due to its stimulating effect, reduce hypervigilance associated with PTSD, and allow reflection on traumatic memories during psychotherapy without being overwhelmed.
“Marijuana, classic hallucinogens, MDMA, and ketamine have all shown some evidence for therapeutic applications in a wide variety of psychiatric and neurological conditions; however, Schedule I status severely limits ability to research,” concluded Suavé. “Most studies to date are small, underpowered, and have other methodological flaws; however, promising results from existing studies suggest that larger studies are warranted.”
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More